|Patent Cooperation Treaty||Published Application||WO2019204818||10/24/2019||2018-209|
Additional Patent Pending
Injuries that involve a degree of muscle tissue loss that exceeds the endogenous regenerative capacity of muscle, resulting in permanent cosmetic and functional deficits of either the injured muscle or the muscle unit, are referred to as volumetric muscle loss (VML) injuries. Current treatment for VML injury involves surgical muscle transfer, although these procedures are often associated with poor engraftment and donor site
UC Berkeley and U.Va researchers have developed a new technology for the treatment of VML injuries that overcomes the limitations associated with current treatments for VML injury. The Matrix Assisted Cell Transplantation (MACT) technology developed by the researchers employs “bioinspired” materials designed to emulate regulatory processes that modulate cell function in the stem/progenitor cell microenvironment. The technology includes: 1) peptide ligands to imitate the natural extracellular matrix (ECM); 2) proteolytic remodeling via matrix metalloproteinase (MMP) sensitive peptide crosslinks; and, 3) growth factors with engineered density and presentation.
The technology and the materials used have been shown to significantly improve donor survival after transplantation, promote angiogenesis, and encourage donor cell integration with the host tissue.